Patents by Inventor Christian Frauendorf

Christian Frauendorf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Products and compositions
    Patent number: 11987794
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: May 21, 2024
    Assignee: Silence Therapeutics GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Adrien Weingärtner, Lucas Bethge, Christian Frauendorf, Alison Gallafent
  • Nucleic acid linked to a trivalent glycoconjugate
    Patent number: 11912993
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: February 27, 2024
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Christian Frauendorf, Mark Cameron
  • Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
    Patent number: 11873489
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 16, 2024
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Lucas Bethge, Judith Hauptmann, Christian Frauendorf, Adrien Weingärtner
  • Nucleic acids for inhibiting expression of LPA in a cell
    Patent number: 11499153
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 15, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingärtner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20220290143
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 15, 2022
    Inventors: Judith HAUPTMANN, Dmitry SAMARSKY, Adrien WEINGÄRTNER, Lucas BETHGE, Christian FRAUENDORF, Alison GALLAFENT
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220290144
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 15, 2022
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingartner, David Anthony Rider
  • Products and compositions
    Patent number: 11414660
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: August 16, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Adrien Weingärtner, Lucas Bethge, Christian Frauendorf, Alison Gallafent
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220170016
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 2, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • Nucleic acids for inhibiting expression of LPA in a cell
    Patent number: 11319537
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 3, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingärtner, David Anthony Rider
  • Further novel oligonucleotide-ligand conjugates
    Patent number: 11299738
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 12, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Dmitry Samarsky, Christian Frauendorf
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20220090067
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorders.
    Type: Application
    Filed: March 31, 2021
    Publication date: March 24, 2022
    Inventors: Judith Hauptmann, Dmitry Samarsky, Christian Frauendorf
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20220025377
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Inventors: Sibylle DAMES, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
    Publication number: 20220017899
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 20, 2022
    Inventors: Verena Aumiller, Sibylle Dames, Steffen Schubert, Judith Hauptmann, Christian Frauendorf, Marie Wikstrom Lindholm, Adrien Weingartner, Lucas Bethge
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220002722
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 6, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Flauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • Products and compositions
    Patent number: 11174483
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: November 16, 2021
    Assignee: Silence Therapeutics GmbH
    Inventors: Sibylle Dames, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • Products and compositions
    Patent number: 11015198
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorders.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 25, 2021
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Christian Frauendorf
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20210123048
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: November 13, 2018
    Publication date: April 29, 2021
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingärtner, David Anthony Rider
  • FURTHER NOVEL OLIGONUCLEOTIDE-LIGAND CONJUGATES
    Publication number: 20210087570
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Application
    Filed: April 5, 2018
    Publication date: March 25, 2021
    Inventors: Dmitry SAMARSKY, Christian FRAUENDORF
  • NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE
    Publication number: 20210079397
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Application
    Filed: November 25, 2020
    Publication date: March 18, 2021
    Inventors: Christian Frauendorf, Mark Cameron
  • Nucleic acid linked to a trivalent glycoconjugate
    Patent number: 10913945
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: February 9, 2021
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Christian Frauendorf, Mark Cameron